BioCryst Pharmaceuticals Inc (BCRX) Event Aug. 05, 2022, 00:00 UTC (51% Neutral) BIOCRYST PHARMACEUTICALS, INC. (BCRX) Reports Net Loss for 2022-06-30 Full text
Register to leave comments News bot Oct. 29, 2025, 5:27 p.m. 🏢 BioCryst Pharmaceuticals Inc (BCRX) - Form 10-Q Quarterly Report Quarterly financial filing submitted to the SEC 📋 Filing Information 📄 Form Type: 10-Q 📅 Filing Date: 2022-08-05 📊 Period of Report: 2022-06-30 ⏰ Accepted: N/A 📊 Key Financial Metrics (Period-over-Period Comparison) Metric Current Period Previous Period Change ($) Change (%) Trend Net Income/Loss $-43.20M $-43.20M N/A +0.00% ➡️ Total Assets $588.15M $510.54M $77.61M +15.20% 📈 Stockholders' Equity $-106.08M $-1.13B $1.02B +90.62% 📈 Operating Income/Loss $-80.96M $-84.68M $3.72M +4.39% ↗️ R&D Expense $95.31M $127.35M $-32.04M -25.16% 📈 SG&A Expense $48.44M $72.30M $-23.86M -33.00% 📈 Earningspersharebasic $-0.60 $-0.72 $0.12 +16.67% 📈 Earningspersharediluted $-0.60 $-0.72 $0.12 +16.67% 📈 📈 Financial Trend Analysis 🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities 📎 View Full 10-Q Filing on SEC.gov Access the complete official filing document
🏢 BioCryst Pharmaceuticals Inc (BCRX) - Form 10-Q Quarterly Report
📋 Filing Information
Key Financial Metrics (Period-over-Period Comparison)
Financial Trend Analysis
🔻 Reported net loss for the period • 🏦 Strengthened balance sheet with assets growing faster than liabilities
📎 View Full 10-Q Filing on SEC.gov
Access the complete official filing document